Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Quarterly Earnings Results

Amylyx Pharmaceuticals (NASDAQ:AMLX) issued its earnings results on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06), Zacks reports.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $3.00 on Tuesday. The firm has a market capitalization of $205.64 million, a PE ratio of -0.79 and a beta of -0.54. The firm’s 50-day moving average is $3.58 and its two-hundred day moving average is $3.85. Amylyx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $19.42.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the sale, the chief executive officer now directly owns 3,201,247 shares of the company’s stock, valued at approximately $11,108,327.09. This represents a 0.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the sale, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,169 shares of company stock valued at $97,274 in the last ninety days. Company insiders own 11.70% of the company’s stock.

Analysts Set New Price Targets

AMLX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $3.00 to $11.00 in a report on Monday, November 18th. Finally, Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.